Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yoo‐Seok Yoon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7621-8557; OpenAlex author ID A5041499733, A5056020286, A5144281714. Sources: OpenAlex.

Their work

Papers
38 (first author 7, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
139
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 4 papers · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 6 papers · 2022: 2 papers · 2023: 6 papers · 2024: 3 papers · 2025: 5 papers · 2026: 2 papers

Papers 38

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  3. "Obesity Paradox" as a new insight from long-term survivors in pancreatic cancer patients. Co-author DOI 10.1016/j.hpb.2025.03.450↗
  4. Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer. Co-author DOI 10.1186/s12967-025-06599-9↗
  5. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Co-author DOI 10.1245/s10434-025-17389-4↗
  6. Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-t… Last author DOI 10.14701/ahbps.25-120↗
  7. Development of an Immunodeficient Pig Model for Pancreatic Cancer Xenotransplantation Using Splenectomy, Thymectomy, and Oral Immunosuppression. First author DOI 10.3390/medicina61040586↗
  8. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study. Last author DOI 10.1016/j.pan.2024.03.013↗
  9. Feasibility of Early Diagnosis of Pancreatic Cancer using reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine Last author DOI 10.21203/rs.3.rs-5011761/v1↗
  10. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
  11. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  12. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  13. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  14. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival a… First author DOI 10.1245/s10434-022-13043-5↗
  15. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Co-author DOI 10.3390/cancers15153850↗
  16. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives. Co-author DOI 10.4251/wjgo.v15.i6.911↗
  17. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  18. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic C… Co-author DOI 10.5009/gnl20312↗
  19. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: Retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2021.106050↗
  20. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… Co-author DOI 10.1016/j.pan.2021.02.022↗
  21. Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma: An Analysis of Oncologic Outcomes According to the Recurrence Type. Last author DOI 10.1097/as9.0000000000000096↗
  22. Impact of Acute Inflammation on the Survival Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000520063↗
  23. Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. First author DOI 10.3390/cancers13174454↗
  24. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  25. Prognosis prediction of pancreatic cancer after curative intent surgery using imaging parameters derived from F-18 fluorodeoxyglucose positron emission tomogra… First author DOI 10.1097/md.0000000000021829↗
  26. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to panc… Last author DOI 10.14701/ahbps.2020.24.2.127↗
  27. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  28. Laparoscopic subtotal pancreatectomy with radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer. First author DOI 10.1016/j.suronc.2018.12.006↗
  29. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/s00268-016-3798-1↗
  30. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.12.038↗
  31. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. Co-author DOI 10.1111/apm.12705↗
  32. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1010428317718403↗
  33. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma. First author DOI 10.1002/jso.24133↗
  34. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic d… Co-author DOI 10.1016/j.amjsurg.2014.06.038↗
  35. Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2014.12.051↗
  36. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. Co-author DOI 10.1111/cas.12744↗
  37. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. Co-author DOI 10.3346/jkms.2015.30.3.259↗
  38. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Co-author DOI 10.1111/j.1440-1827.2011.02772.x↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ho‐Seong Han · 31 shared papers, 2012–2025 · strength 4.37
  2. Boram Lee · 7 shared papers, 2021–2025 · strength 1.59
  3. Jai Young Cho · 14 shared papers, 2012–2025 · strength 1.46
  4. Jun Suh Lee · 7 shared papers, 2021–2025 · strength 1.32
  5. Yeshong Park · 5 shared papers, 2023–2025 · strength 1.28
  6. Jin‐Hyeok Hwang · 13 shared papers, 2012–2025 · strength 1.27
  7. MeeYoung Kang · 5 shared papers, 2023–2025 · strength 1.21
  8. Jin‐Young Jang · 8 shared papers, 2021–2025 · strength 1.16
  9. Jaihwan Kim · 10 shared papers, 2015–2025 · strength 1.13
  10. Wooil Kwon · 6 shared papers, 2017–2026 · strength 0.92
  11. Jong-Chan Lee · 6 shared papers, 2017–2024 · strength 0.80
  12. Haeryoung Kim · 7 shared papers, 2012–2024 · strength 0.73
  13. Jin Seok Heo · 5 shared papers, 2021–2023 · strength 0.66
  14. Chang-Sup Lim · 4 shared papers, 2021–2026 · strength 0.65
  15. In Woong Han · 4 shared papers, 2021–2026 · strength 0.59
  16. Kwangrok Jung · 3 shared papers, 2021–2025 · strength 0.55
  17. Jin Peng He · 3 shared papers, 2023–2024 · strength 0.51
  18. Jinju Kim · 2 shared papers, 2024–2025 · strength 0.50
  19. Sang‐Jae Park · 4 shared papers, 2019–2023 · strength 0.48
  20. Dae Wook Hwang · 4 shared papers, 2015–2023 · strength 0.47
  21. Tsutomu Fujii · 3 shared papers, 2023–2026 · strength 0.45
  22. Yoon Soo Chae · 2 shared papers, 2025–2026 · strength 0.44
  23. Hye‐Sol Jung · 2 shared papers, 2025–2026 · strength 0.44
  24. Yeon Bi Han · 2 shared papers, 2024–2025 · strength 0.42
  25. Hongbeom Kim · 3 shared papers, 2021–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.